Yakult Vision 2020 Phase II Plan ( )

Similar documents
Outline of the Business Alliance

Food and Beverage Distribution. Business Strategies

FY2017 to FY2019 Medium-Term Management Plan. March 29, 2017 Shimadzu Corporation President and CEO Teruhisa Ueda

Dentsu 2017 and Beyond -Innovation Reinvention-

Daiwa Securities Group Medium-Term Management Plan. Passion for the Best Daiwa Securities Group Inc. has released Passion for the Best 2020, the

2, % % (0.8) % % (2.6) % % (1.5)

Citizen Global Plan 2018 (Medium-Term Management Plan Briefing)

The Middle-Term Management Vision. June, 2010

Kirin Group Financial Results for the 1Q May 10, 2018 Kirin Holdings Company, Limited

Mobilizing our strengths to build foundations for a strong future

Company Overview / CSR Management

The Mochida Pharmaceutical Group s Medium Term Management Plan

Results Meeting for 1H of the Fiscal Year Ending March 2018

Lion Announces Its New Management Vision and Medium-Term Management Plan

Nihon Kohden draws up a new mid-term business plan

New Medium-term Management Plan

The Mochida Pharmaceutical Group s Medium Term Management Plan

New Medium-term Management Plan Breakthrough for the Next Decade

Name of Representative:

Kyocera Corporation Telephone Conference Call (January 29, 2009)

In Tune for Further Growth

Consolidated Financial Results

MESSAGE TO SHAREHOLDERS AND OTHER INVESTORS

COMPANY RESEARCH AND ANALYSIS REPORT

From a Leader in Japan to a Winner Worldwide

Results Briefing FY2017

Scientific Solutions Business Strategy

NEWS RELEASE SHOWA DENKO K.K. 13-9, Shiba Daimon 1-chome Minato-ku, Tokyo

Capital Market Day June 12, 2012

Initiatives for Realizing the Long-term Plan for 2010

Long-term Management Vision 2030 and Medium-term Management Plan 2020

Notice of Outsourcing of Logistics Operations and of Transfer of Logistics Subsidiary and Associated Fixed Assets

Mazda Motor Corporation FISCAL YEAR MARCH 2018 FULL YEAR FINANCIAL RESULTS (Speech Outline)

BALANCE SCORECARD. Introduction. What is Balance Scorecard?

Financial Results Meeting: The 1st 3 Months of FY Ending March (April 1, 2016 June 30, 2016) August 9, 2016

Details about profit from operating activities and other categories of profit will be provided later in the presentation.

Growth Plan. October 29, 2014

Review and Improvement of CSR Activities

Canon Marketing Japan Inc. Second Quarter 2016 Results

First Half Results Briefing for Year Ending March 31, 2018

Strategic Capital and Business Alliance Between Fujifilm, Taisho Pharmaceutical and Toyama Chemical

Midterm Management Plan

Today, I would like to start with outline of our group reorganization.

Corporate Profile KATO SANGYO Co., Ltd

[Results main points]

Strategy Agricultural Products

Santen Pharmaceutical Co., Ltd. Financial Performance and Outlook Year Ended March 31, 2005

Sustainable Growth with Returns in Waters

Canon Inc. First Quarter 2018 Analyst Meeting Wednesday, April 25, 2018

(Translation) September 14, [Reference] Shiseido s Global Vision: China at the Helm of Broadbased Expansion Strategy

FY2/2016 Third Quarter Results Presentation

The Growth Strategy of Shionogi. September, 2011

Organo Corporation. Report on the Second Quarter Financial Results for the Term Ending March 31, (Date: November 9, 2010 Hours: 16.

Extensive Network and Reliable Brand Nationwide post-office and delivery

Notice of Termination of Capital and Business Alliance with WPP Group

Our strategy 14 NOKIA IN 2017

Results of the 16th MTP. Overview of the 17th MTP.

Konica Minolta to Acquire Invicro (US)

Nomura Investment Forum 2012

Three-Year Rolling Plan Sales Strategies

Moberg Pharma AB A DIFFERENT KIND OF PHARMA COMPANY

Retail Support Equipment & Systems Group

2030 Long-term Management Vision and 2020 Medium-term Management Plan

Shiseido Growth Strategies and Beauty Consultants

Earnings of FY2018/3 3Q

Indian Pharmaceutical Industry. January 2018

Tecan Group 34 th Annual J.P. Morgan Healthcare Conference DR. DAVID MARTYR, CEO JANUARY 14, 2016 SAN FRANCISCO, USA

Results Briefing for Year Ended March 31, 2018

I would like to review our business results for the first quarter of fiscal Before giving specific details of the financial results, I would

Financial Results Meeting: The 1st 6 Months of FY Ending March 2018 (April 1, 2017 September 30, 2017) November 10, 2017

Summary of Business Results for the Fiscal Year ended March 31, 2014

Canon Inc. Third Quarter 2017 Analyst Meeting Tuesday, October 24, 2017

Organo Corporation. Report on the Second Quarter Financial Results for the Term Ending March 31, November 10, 2014

Mizuno Corporation The 100th Period (Year ended March 31, 2013)

Brands and Lines at a Glance

2002 Porter Prize Winners. Division of Multiple-Business Company Category Winners

The Future of Forestry. Jefferies 2014 Global Industrials Conference August 11, 2014

Business Overview. Chiyoda Corporation. May 11, Chiyoda Corporation 2018, All Rights Reserved.

Environment. Our Vision. Material Issue 1. New Eco Vision 2050

Interview with the President

More Dreams for Your Life ANNUAL REPORT 2004

Global Marketing INTRODUCTION GLOBAL MARKETING GLOBALIZATION 9/26/2014

Investors Information Meeting

HIKMA PHARMACEUTICALS PLC. Merrill Lynch Middle East & North Africa (MENA) Conference 13 December r 2005

To achieve our vision of helping patients around the world, we are creating an organization that can fully leverage diversity.

Biopharmaceuticals Investor & Analyst Day

The Group s New Challenges Lead to Dramatic Growth

Ratio to. Net Sales on Oct. 6

Company overview and strategic direction

Medium-Term Management Plan

The value chain supporting growth

Results Briefing FY2012

Corporate Presentation & Offer for SAP ATTP December 2015

Management of Fuji Xerox

May 18, FUJI SOFT ABC., Inc. Hiroshi Nozawa Representative Director, Chairman and President

Mitsui Chemicals to Draw up the Grand Design and to Reorganize Business Structure

Provide top-notch service

We encourage readers to review our complete legal statement on Disclaimer page.

BASF signs agreement to acquire significant parts of Bayer s seed and non-selective herbicide businesses. October 13, 2017

Financial Results for the Fiscal Year Ended December 31, 2017

Transcription:

Yakult Vision 2020 Phase II Plan (2014 2016) May 13, 2014 Yakult Honsha Co., Ltd.

Table of Contents Outline of Long-term Vision Outline of long-term vision P2 Review of Phase I Plan (2011 2013) Company-wide goals and results for Phase I P4 6 Phase II Plan (2014 2016) (1) Concept of Phase II plan formulation P8 9 (2) Phase II company-wide strategy P10 (3) Quantitative goals P11 15 (4) Concept of management benchmarks P16 (5) Segment-based strategy P17 24

Outline of Long-term Vision 1

Outline of Long-term Vision Yakult Vision 2020 is a medium- to long-term management plan formulated in the year of its 75th anniversary to clarify what it aspires to be in the next 10 years. Qualitative goals Quantitative goals Corporate philosophy We contribute to the health and happiness of people around the world through pursuit of excellence in life science in general and our research and experience in microorganisms in particular Number of bottles of dairy products sold per day worldwide Consolidated sales FY2009 26.40 million bottles/day 290.7 billion FY2020 36.50 million bottles/day 500.0 billion Up 10 million bottles About double Yakult Vision 2020 Let s Build Yakult s Future Together! Consolidated operating income 19.0 billion 50.0 billion About triple - Let s promote the idea that a healthy intestinal tract leads to a long life, to as many people as possible on the earth! - Let s apply our unique combination of preventative medicine and therapeutic medicine to realize a healthy society! - Let s offer satisfaction and happiness to our customers and ourselves by whole-heartedly delivering the best technology with gratitude! Implementation in three phases over 10 years Phase I Phase II Phase III 2011 2013 2014 2016 2017 2020 2

Review of Phase I Plan (2011 2013) 3

Review of Phase I Plan (2011 2013) Company-wide Goals and Results for Phase I [1] Quantitative goals Sales (billion ) 650 600 550 500 450 400 350 300 250 200 150 100 50 0 Sales Operating income Number of bottles of dairy products (results) 290.7 billion Number of bottles of dairy products (initial plan) 26.40 million bottles/day 19.0 billion 58th accounting period (2009) 345.0 billion Plan Goals achieved 350.3 billion Results 62nd accounting period (2013) 32.37 million bottles/day 32.0 billion 26.0 billion Plan Results 30.11 million bottles/day (plan) 65th accounting period (2016) 500.0 billion Operating income (billion ) 130 36.50 million bottles/day 50.0 billion 69th accounting period (2020) before the plan Phase I Phase II Phase III 120 110 100 90 80 70 60 50 40 30 20 10 0 Plan Result (achievement rate of target) Dairy products sold worldwide 30.11 million bottles/day 32.37 million bottles/day (107.5%) Consolidated sales 345.0 billion 350.3 billion (101.5%) Consolidated operating income 26.0 billion 32.0 billion (123.1%) 4

Review of Phase I Plan (2011 2013) Company-wide Goals and Results for Phase I [2] Significance of Phase I Run-up period before a leap forward Prepare a base of business model, for goal of FY2020 In the Japanese food and beverages business, we built a base for regrowth in the mature domestic market. We bolstered our research and development bases, improved the efficiency of production bases through reorganization, and promoted the value of probiotics, which is the core of our business. As a result, we achieved a certain level of success. In the overseas food and beverages business, we strived to cultivate and expand the markets and strengthened the supply system, which drove forward the overall performance of the business. While the pharmaceutical business faced tough conditions due to the impact of NHI drug price revision, we worked to enhance the business with focus on oncology by driving forward development of products in the pipeline. 5

Review of Phase I Plan (2011 2013) Company-wide Goals and Results for Phase I [3] Segment Food and Beverages (Japan) Food and Beverages (Overseas) Companywide Pharmaceuticals Achievement in the 3 years Introduction of the executive officer system (in June 2011) Strengthening of research and development bases - Yakult Central Institute for Microbiological Research: construction of 4 research blocks (started in October 2012; to be completed in 2015) Reorganization and streamlining of production bases - Driving forward the second phase of capital investment plan (reorganization from 14 plants to 11 plants) - Full-scale operation of Hyogo Miki Plant (December 2012) Strengthening of existing brands - Improvement of core products value (launch of New Yakult in November 2013) Continued implementation of value promotion activities Increasing marketing population and increase of population ratio - Started sales in 2 new countries and 5 new cities in China (the number of countries and regions where we sell our products increased to 32) Enhancement of supply bases - Driving forward plant capital investment (production system of 31 million bottles/day at 22 bases) Approval of adjuvant XELOX treatment with Elplat Expanded indications of Elplat - Approval for treating pancreas cancer and promotion of the process for gaining approval for treating stomach cancer Driving forward development of pipeline products 6

Phase II Plan (2014 2016) 7

(1) Concept of Phase II Plan Formulation [1] Significance of Phase II Plan Yakult Group aims for a dramatic growth, primarily through business promotion in accordance with the corporate philosophy, based on the preparation of a business model that is continuing from Phase I. Corporate philosophy We contribute to the health and happiness of people around the world through pursuit of excellence in life science in general and our research and experience in microorganisms in particular Phase I 2011 2013 Run-up period before a leap forward Prepare a base of business model, for goal of FY2020 Phase II 2014 2016 Dramatic growth period Phase III 2017 2020 Long-term vision realization period 8

(1) Concept of Phase II Plan Formulation [2] Concept for achieving goals We will further promote globalization by spreading the probiotics value promotion activities around the world, which is the core of the Yakult business. We aim for sustainable growth by strengthening our research and development capabilities as well as by offering unique products whose effectiveness has been scientifically proven and providing services that only Yakult can provide. The entire group will work together to contribute to people around the world (local communities) through practice of the corporate philosophy. 9

(2) Phase II Company-wide Strategy [Continued promotion of the global business portfolio strategy] Continue to grow the group by deploying the most appropriate strategies for each phase of introduction, growth, maturation, and rebuilding in respective areas of the global market. Also, drive forward development of the foundation of the domestic business, which leads the nextgeneration global businesses. Expand and cultivate markets (penetration and expansion) Rebuild business model Introduction period Growth period Maturation period Rebuilding period Cycle leading to Regrowth based on the new model Growth period Market Maturation Phases in Global Market Growth period Maturation period Rebuilding period Introduction period Introduction period Regrowth Growth period Growth period 10

(3) Quantitative Goals: [1] Company-wide Goals Sales (billion ) 650 600 550 500 450 400 350 300 250 200 150 100 Number of bottles of dairy products (results,phase ll plan ) Number of bottles of dairy products (initial plan) 27.50 million bottles/day 305.9 billion Sales 20.4 billion Operating income 350.3 billion 32.37 million bottles/day 30.11 million bottles/day (plan) 420.0 billion 32.0 billion 37.10 million bottles/day 43.0 billion 36.50 million bottles/day 500.0 billion Operating income (billion ) 50.0 billion 130 120 110 100 90 80 70 60 50 40 30 20 50 10 0 59th accounting period (2010) 62nd accounting period (2013) 65th accounting period (2016) 69th accounting period (2020) 0 1 year before the plan Phase I Phase II Phase III Dairy products sold worldwide 37.10 million bottles/day (up 4.73 million bottles/day from Phase I) Consolidated sales 420.0 billion (up 69.7 billion from Phase I) Consolidated operating income 43.0 billion (up 11.0 billion from Phase I) We aim to achieve company-wide 2020 quantitative goals ahead of schedule 11

(3) Quantitative Goals: [2] Marketing Population and Population Ratio (million people) 2,500 2,000 1,500 Overseas population Domestic population Overseas population ratio Domestic population ratio 8.0% 6.9% 7.0% 7.5% 1,960 million 7.0% 1,700 million 130 million 6.0% 1,450 million 130 million 5.0% 130 million 4.0% 1,000 500 1,320 million 1,570 million 1,830 million 1.4% 1.5% 1.5% 3.0% 2.0% 1.0% 0 FY2010 (results) FY2013 (results) FY2016 (plan) 1 year before the plan Phase I Phase II *Population ratio: Dairy products sold per day/marketing population 0.0% 12

(3) Quantitative Goals: [3] Number of Dairy Products Sold per Day (million bottles) 40.00 30.00 20.00 10.00 Food and beverages (Overseas) 27.50 million 8.77 million (population ratio: 6.9%) 18.73 million (population ratio: 1.4%) 32.37 million 8.96 million (population ratio: 7.0%) 23.41 million (population ratio: 1.5%) Food and beverages (Japan) [vs. 2013] 37.10 million 9.60 million (population ratio: 7.5%) 27.50 million (population ratio: 1.5%) +4.73 million (+14.6%) +0.64 million (+7.1%) +4.09 million (+17.5%) 0.00 FY2010 (results) FY2013 (results) FY2016 (plan) 1 year before the plan Phase I Phase II 13

(3) Quantitative Goals: [4] Consolidated Sales By segment (billion ) 500 400 300 200 Food and Beverages (Japan) Food and Beverages (Overseas) Pharmaceuticals Others (Cosmetics, etc.) Adjustments (eliminations of intracompany transactions, etc.) 305.9 billion 17.1 billion 38.8 billion 71.6 billion 350.3 billion 18.0 billion 35.3 billion 118.8 billion 420.0 billion 20.0 billion +2.0 billion (+11.1%) 50.0 billion 150.0 billion [vs. 2013] +69.7 billion (+19.9%) +14.7 billion (+41.6%) +31.2 billion (+26.3%) 100 189.7 billion 200.4 billion 216.0 billion +15.6 billion (+7.8%) 0-11.5 billion -22.3 billion -16.0 billion -100 FY2010 (results) FY2013 (results) FY2016 (plan) 1 year before the plan Phase I Phase II 14

(3) Quantitative Goals: [5] Consolidated Operating Income By segment (billion ) 80 60 40 Food and Beverages (Japan) Food and Beverages (Overseas) Pharmaceuticals Others (Cosmetics, etc.) Adjustments (eliminations of intracompany transactions, etc.) 20.4 billion 32.0 billion 1.3 billion 8.5 billion 43.0 billion 1.0 billion [vs. 2013] +11.0billion (+34.4%) -0.3 billion (-23.1%) 13.0 billion +4.5 billion (+52.9%) 20 10.2 billion 12.9 billion 27.8 billion 34.0 billion +6.2 billion (+22.3%) 0 11.0 billion -0.6 billion 9.7 billion 12.0 billion -13.1 billion -15.5 billion -17.0 billion +2.3 billion (+23.7%) -20 FY2010 (results) FY2013 (results) FY2016 (plan) 1 year before the plan Phase I Phase II 15

(4) Concept of Management Benchmarks [1] Operating income margin In Yakult Vision 2020, we are targeting sales of 500.0 billion and operating income of 50.0 billion (operating income margin of 10%) in 2020. We will continue to improve profitability and aim to achieve 10% operating income margin in 2016. [2] Return on equity (ROE) We will aim for an ROE of 9% in 2016 by improving management efficiency while working to maximize net income. [3] Return on assets (ROA) We will aim for an ROA of 9% in 2016 by improving investment efficiency while working to maximize ordinary income. [4] Equity ratio We will aim to improve it to 57% in 2016 by further strengthening our financial structure. 16

(5) Segment-based Strategy: [1] Food and Beverages (Japan) Business policy Establish brand superiority in the probiotics market Strengthen R&D prowess to take the lead in the preventative medicine era Strengthen operating base and promote reforms Offer safe, secure and highquality products Pursue value promotion closely linked to local communities Strengthen and innovate a business model that can adapt to the changing times 17

(5) Segment-based Strategy: [1] Food and Beverages (Japan) Quantitative goals Qualitative goals No. of bottles of dairy products sold Consolidated sales FY2016 target 9.60 million bottles/day 216.0 billion Change vs. FY2013 +0.64 million bottles/day +15.6 billion Achieve continuous growth in the mature domestic market Consolidated operating income 12.0 billion +2.3 billion Pillars of the strategy Dairy products: Strengthen existing brand and develop products with new evidence Juices and soft drinks: Strengthen lineup of functional health drinks and food products Pursue value promotion activities that combine advertising, PR and sales channels (home delivery/route sales) Improve management quality of the group and enhance organization Strengthen and expand contact with customers through business model innovation. 18

(5) Segment-based Strategy: [2] Food and Beverages (Overseas) Business policy Countries and regions where we sold in 2013 Countries aimed for entry 2013 2016 32 countries and regions 41 countries and regions (aimed) 19

(5) Segment-based Strategy: [2] Food and Beverages (Overseas) Quantitative goals Qualitative goals No. of bottles of dairy products sold FY2016 target 27.50 million bottles/day Change vs. FY2013 +4.09 million bottles/day Propagate the message of Yakult and spread the joy of health Consolidated sales Consolidated operating income 150.0 billion 34.0 billion +31.2 billion +6.2 billion Expand and cultivate global markets Pillars of the strategy Continue to grow business of existing operations Stabilize management of newly established operations and grow their businesses Enter into new countries 20

(5) Segment-based Strategy: [3] Pharmaceuticals Business policy Aim to become Japan s No. 1 oncology company In pursuit of healthy life for people around the world 21

(5) Segment-based Strategy: [3] Pharmaceuticals Quantitative goals Qualitative goals Consolidated sales Consolidated operating income FY2016 target 50.0 billion 13.0 billion Change vs. FY2013 +14.7 billion +4.5 billion Contribute to the health of people around the world by making innovations in the field of oncology Pillars of the strategy Maximize sales of Elplat Maintain sales of existing products and long-term listed products Further increase share by boosting generic product lineup Build foundation for continuous development of new drugs by enhancing drug candidate pipeline 22

(5) Segment-based Strategy: [4] Others (Cosmetics, Etc.) Business policy (Cosmetics) Basic skin care products with moisturizing ingredients based on lactobacillus Cosmetic development with focus on safety and security Health and happiness of people based on the concept of intestinal health is a direct factor in producing beautiful, healthy skin Intestinal health is a direct factor in producing beautiful, healthy skin : tone up the internal organs/stomach with lactobacillus drinks and protect the health of the outside of the body/skin with cosmetics Value promotion activities with focus on Yakult customers Prepare environment for carrying out counseling 23

(5) Segment-based Strategy: [4] Others (Cosmetics, Etc.) Quantitative goals (Total for Others) Consolidated sales Consolidated operating income Pillars of the strategy (Cosmetics) FY2016 target 20.0 billion 1.0 billion Change vs. FY2013 +2.0 billion -0.3 billion Qualitative goals (Cosmetics) Working as one, Yakult Honsha and marketing companies are making efforts to strengthen and expand the cosmetics business. Marketing strategy activities centered on basic skin care products based on Yakult's proprietary ingredients derived from lactic acid research Strengthen and expand the cosmetics business at marketing companies Promote new customer development by utilizing esthetic salons, and offer Yakult customers Yakult cosmetics as well as food and beverages Study online sales and new sales channels and expand corporate customers 24

The statements in this material with respect to the plans and forecasts are forward-looking statements, except for the facts of the past, and involve uncertainties. Actual business performance may significantly differ from these forecasts due to various factors. Information in this material is not aimed at soliciting any investment. The company does not provide guarantees of any kind regarding the contents of this material. The company or parties providing the information assume no responsibility for any damages resulting from this material.